{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:02:16Z","timestamp":1753887736705,"version":"3.41.2"},"reference-count":10,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients. In this report, we describe the successful treatment of an 84-year-old male patient suffering from severe symptomatic AR and concomitant cardiorenal syndrome with renal failure using a 34-mm Evolut R (Medtronic) self-expanding transcatheter aortic valve replacement. This intervention resulted in the resolution of AR, cardiorenal syndrome, and congestive heart failure symptoms.<\/jats:p>","DOI":"10.15420\/usc.2024.19","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T17:37:50Z","timestamp":1731519470000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Percutaneous Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a High-risk Patient with Cardiorenal Syndrome"],"prefix":"10.15420","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-4595","authenticated-orcid":false,"given":"Deniz","family":"Mutlu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; Center for Coronary Artery Disease, Minneapolis Heart Institute Foundation, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-6748","authenticated-orcid":false,"given":"Ibrahim Halil","family":"Inanc","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Kirikkale Yuksek Ihtisas Hospital, Kirikkale, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-360X","authenticated-orcid":false,"given":"Ozgecan Piril Zanbak","family":"Mutlu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7142","authenticated-orcid":false,"given":"Konstantinos","family":"Marmagkiolis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, MD Anderson Cancer Center, University of Texas, Houston, TX; Department of Cardiology, Tampa General Hospital, University of South Florida, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-4579","authenticated-orcid":false,"given":"Cezar A","family":"Iliescu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, MD Anderson Cancer Center, University of Texas, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-2267","authenticated-orcid":false,"given":"Mehmet","family":"Cilingiroglu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, MD Anderson Cancer Center, University of Texas, Houston, TX;  Department of Cardiology, University of Texas Health Science Center at San Antonio, San Antonio, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6096","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43:561\u2013632. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395; PMID:\u00a034453165.","key":"ref0"},{"doi-asserted-by":"publisher","unstructured":"Aluru JS, Barsouk A, Saginala K, et al. Valvular heart disease epidemiology. Med Sci (Basel) 2022;10. https:\/\/doi.org\/10.3390\/medsci10020032; PMID:\u00a035736352.","key":"ref1","DOI":"10.3390\/medsci10020032"},{"doi-asserted-by":"publisher","unstructured":"Choudhury T, Solomonica A, Bagur R. The Evolut R and Evolut PRO transcatheter aortic valve systems. Expert Rev Med Devices 2019;16:3\u20139. https:\/\/doi.org\/10.1080\/17434440.2019.1557045; PMID:\u00a030518281.","key":"ref2","DOI":"10.1080\/17434440.2019.1557045"},{"unstructured":"Yoon SH, Schmidt T, Bleiziffer S, et al. Transcatheter aortic valve replacement in pure native aortic valve regurgitation. J Am Coll Cardiol 2017;70:2752\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.006; PMID:\u00a029191323.","key":"ref3"},{"doi-asserted-by":"publisher","unstructured":"Urena M, Himbert D, Ohlmann P, et al. Transcatheter aortic valve replacement to treat pure aortic regurgitation on noncalcified native valves. J Am Coll Cardiol 2016;68:1705\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2016.07.746; PMID:\u00a027712786.","key":"ref4","DOI":"10.1016\/j.jacc.2016.07.746"},{"doi-asserted-by":"publisher","unstructured":"Inanc IH, Mutlu D, Marmagkiolis K, et al. Use of Safari 2TM as workhorse wire for left-sided structural heart interventions. Cardiovasc Revasc Med 2024;64:21\u20134. https:\/\/doi.org\/10.1016\/j.carrev.2024.02.003; PMID:\u00a038388247.","key":"ref5","DOI":"10.1016\/j.carrev.2024.02.003"},{"doi-asserted-by":"publisher","unstructured":"Yao J, Lu Z-N, Modine T, et al. Evaluation of the safety and efficacy of a novel Anatomical classification and dUal anchoRing theory to Optimize the tavR strategy for pure severe Aortic regurgitation (AURORA): a prospective cohort study. BMC Cardiovasc Disord 2022;22:445. https:\/\/doi.org\/10.1186\/s12872-022-02883-4; PMID:\u00a036243693.","key":"ref6","DOI":"10.1186\/s12872-022-02883-4"},{"doi-asserted-by":"publisher","unstructured":"Wernly B, Eder S, Navarese EP, et al. Transcatheter aortic valve replacement for pure aortic valve regurgitation: \u201con-label\u201d versus \u201coff-label\u201d use of TAVR devices. Clin Res Cardiol 2019;108:921\u201330. https:\/\/doi.org\/10.1007\/s00392-019-01422-0; PMID:\u00a030737532.","key":"ref7","DOI":"10.1007\/s00392-019-01422-0"},{"doi-asserted-by":"crossref","unstructured":"Shi J, Wei L, Chen Y, et al. Transcatheter aortic valve implantation with J-valve: 2-year outcomes from a multicenter study. Ann Thorac Surg 2021;111:1530\u20136. https:\/\/doi.org\/10.1016\/j.athoracsur.2020.06.139; PMID:\u00a032980330.","key":"ref8","DOI":"10.1016\/j.athoracsur.2020.06.139"},{"doi-asserted-by":"publisher","unstructured":"Vahl TP, Thourani VH, Makkar RR, et al. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet 2024;403:1451\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(23)02806-4; PMID:\u00a038552656.","key":"ref9","DOI":"10.1016\/s0140-6736(23)02806-4"}],"container-title":["US Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T17:37:55Z","timestamp":1731519475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":10,"URL":"https:\/\/doi.org\/10.15420\/usc.2024.19","relation":{},"ISSN":["1758-390X","1758-3896"],"issn-type":[{"type":"electronic","value":"1758-390X"},{"type":"print","value":"1758-3896"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"article-number":"e20"}}